vvDD-hIL2-RG-1
AXP000098.2 · Oncolytic virus
- Platform
- vaccinia virus (Western Reserve, TK- VGF-)
- Originator
- University of Pittsburgh
- Sponsor
- Allegheny Health Network Research Institute
Names
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- Western Reserve
- Replication
- conditionally replicating
- Modifications
- J2R (thymidine kinase) and vaccinia growth factor deleted
- Transgenes
- IL2 (matrix-anchored)
- Route
- intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07001592 | Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors | Recruiting | Phase 1 | 2025-05-06 | 2028-04 | 18 | Esophageal Cancer; Gastric Adenocarcinoma; Gastric Cancer; Gastric Neoplasms; Liver Cancer; Liver Metastasis; MSI-H; MSS; MSS-CRC; Peritoneal Cancer; Peritoneal Carcinoma; Peritoneal Metastases |
Recent changes
No changes recorded in its trials yet.
Notes
Double-deleted vaccinia carrying a tumour-matrix-anchored human IL-2; phase 1 by intratumoral injection in gastrointestinal and peritoneal tumours (NCT07001592, recruiting since June 2025). Dosing of at least one patient inferred from the recruiting status, not confirmed by a report.
How to cite
vvDD-hIL2-RG-1 (AXP000098.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000098.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.